TY - JOUR
T1 - Predicting the likelihood of nonsentinel lymph node metastases in triple negative breast cancer patients with a positive sentinel lymph node
T2 - Turkish federation of breast disease associations protocol MF09-01
AU - Ozbas, Serdar
AU - Ozmen, Vahit
AU - Igci, Abdullah
AU - Muslumanoglu, Mahmut
AU - Ozcinar, Beyza
AU - Balkan, Mujdat
AU - Aydogan, Fatih
AU - Canda, Tulay
AU - Harmancioglu, Omer
AU - Aksaz, Erol
AU - Gulluoglu, Bahadir M.
AU - Kayahan, Munire
AU - Ozaslan, Cihangir
AU - Canturk, N. Zafer
AU - Mersin, Hakan
AU - Utkan, Zafer
AU - Kocak, Savas
AU - Ulufi, Nalan
AU - Polat, Ayfer Kamali
AU - Andacoglu, Oya
AU - Soran, Atilla
PY - 2012/2
Y1 - 2012/2
N2 - Background: Triple negative (TN) tumor has a relatively high rate of recurrence and distant metastasis, but results of studies revealed that triple positive tumor is an independent predictor of axillary lymph node involvement. Our aim was to evaluate the frequency of nonsentinel lymph node metastasis (NSLNM) involvement in operable TN breast cancer with positive sentinel lymph node (SLN) and predicting the likelihood of NSLNM in this cohort of patients by using 4 different nomograms. Methods: A total of 128 patients with TN and SLN+ underwent complete axillary lymph node dissection in 14 different centers in Turkey. For comparison, we used our previous multicenter MF08-01 Protocol, which identified 441 patients with estrogen receptor (ER +) who had a positive SLN biopsy and underwent subsequent complete axillary lymph node dissection. Turkish, Cambridge, and Stanford nomograms and the Tenon Score system were used to calculate the probability of NSLNM. Results: Patients with TN tumor had a larger tumor size. The actual percentage of NSLN positivity was 41% in the TN group and 47.1% in patient with ER+. The Tenon Score was ≤3.5 in 12% of patients with TN and ER+; the area under the curve in the receiver operating characteristics curve were 0.53 and 0.59, respectively. Based on the Turkish, Cambridge, and Stanford nomograms, areas under the curve were 0.54, 0.53, and 0.61, respectively in patients with TN, and were 0.79, 0.72, and 0.70, respectively, in patients with ER +. Conclusion: Using the Tenon Score system underestimates NSLN positivity, and tested nomograms are not good discriminators of NSLNM in patients with TN and positive SLN.
AB - Background: Triple negative (TN) tumor has a relatively high rate of recurrence and distant metastasis, but results of studies revealed that triple positive tumor is an independent predictor of axillary lymph node involvement. Our aim was to evaluate the frequency of nonsentinel lymph node metastasis (NSLNM) involvement in operable TN breast cancer with positive sentinel lymph node (SLN) and predicting the likelihood of NSLNM in this cohort of patients by using 4 different nomograms. Methods: A total of 128 patients with TN and SLN+ underwent complete axillary lymph node dissection in 14 different centers in Turkey. For comparison, we used our previous multicenter MF08-01 Protocol, which identified 441 patients with estrogen receptor (ER +) who had a positive SLN biopsy and underwent subsequent complete axillary lymph node dissection. Turkish, Cambridge, and Stanford nomograms and the Tenon Score system were used to calculate the probability of NSLNM. Results: Patients with TN tumor had a larger tumor size. The actual percentage of NSLN positivity was 41% in the TN group and 47.1% in patient with ER+. The Tenon Score was ≤3.5 in 12% of patients with TN and ER+; the area under the curve in the receiver operating characteristics curve were 0.53 and 0.59, respectively. Based on the Turkish, Cambridge, and Stanford nomograms, areas under the curve were 0.54, 0.53, and 0.61, respectively in patients with TN, and were 0.79, 0.72, and 0.70, respectively, in patients with ER +. Conclusion: Using the Tenon Score system underestimates NSLN positivity, and tested nomograms are not good discriminators of NSLNM in patients with TN and positive SLN.
KW - Breast carcinoma
KW - Nomogram
KW - Nonsentinel lymph node
KW - Sentinel lymph node
KW - Triple negative
UR - http://www.scopus.com/inward/record.url?scp=84856048621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856048621&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2011.07.004
DO - 10.1016/j.clbc.2011.07.004
M3 - Article
C2 - 22130034
AN - SCOPUS:84856048621
SN - 1526-8209
VL - 12
SP - 63
EP - 67
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 1
ER -